AU2020265327B2 - Method for treating cough by using diaminopyrimidine compound - Google Patents

Method for treating cough by using diaminopyrimidine compound

Info

Publication number
AU2020265327B2
AU2020265327B2 AU2020265327A AU2020265327A AU2020265327B2 AU 2020265327 B2 AU2020265327 B2 AU 2020265327B2 AU 2020265327 A AU2020265327 A AU 2020265327A AU 2020265327 A AU2020265327 A AU 2020265327A AU 2020265327 B2 AU2020265327 B2 AU 2020265327B2
Authority
AU
Australia
Prior art keywords
days
compound
alkylene
saturated
cough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020265327A
Other languages
English (en)
Other versions
AU2020265327A1 (en
Inventor
Ran AN
Huai HUANG
Yuanyuan JIANG
Zhou LAN
Huining LIANG
Yanan Liu
Hongjun Wang
Jin Wang
Yanping Zhao
Liying Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of AU2020265327A1 publication Critical patent/AU2020265327A1/en
Application granted granted Critical
Publication of AU2020265327B2 publication Critical patent/AU2020265327B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020265327A 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound Active AU2020265327B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019085180 2019-04-30
CNPCT/CN2019/085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗咳嗽的方法

Publications (2)

Publication Number Publication Date
AU2020265327A1 AU2020265327A1 (en) 2021-12-16
AU2020265327B2 true AU2020265327B2 (en) 2025-09-11

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020265327A Active AU2020265327B2 (en) 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound

Country Status (11)

Country Link
US (1) US20220211703A1 (enExample)
EP (1) EP3960179B1 (enExample)
JP (1) JP7665529B2 (enExample)
KR (1) KR102935436B1 (enExample)
CN (1) CN114007619B (enExample)
AU (1) AU2020265327B2 (enExample)
BR (1) BR112021021600A2 (enExample)
MX (1) MX2021013338A (enExample)
SG (1) SG11202111877TA (enExample)
TW (1) TWI736243B (enExample)
WO (1) WO2020221274A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途
WO2019085916A1 (zh) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557372C (en) * 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
EP1924564B1 (en) * 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
AU2007304280B2 (en) 2006-10-04 2013-01-31 F. Hoffmann-La Roche Ag Process for synthesis of phenoxy diaminopyrimidine derivatives
AU2014308606B2 (en) * 2013-08-23 2017-08-03 Afferent Pharmaceuticals Inc. Diaminopyrimidine P2X3 and P2X 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
DK3355889T3 (da) * 2015-09-29 2023-05-15 Afferent Pharmaceuticals Inc Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste
AU2017237929B2 (en) * 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途
WO2019085916A1 (zh) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAYID ABDULQAWI ET AL: "P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study", THE LANCET (2015), 385 (9974), pages 1198 - 1205, DOI: 10.1016/S0140-6736(14)61255-1 *

Also Published As

Publication number Publication date
EP3960179B1 (en) 2026-03-18
WO2020221274A1 (zh) 2020-11-05
CN114007619A (zh) 2022-02-01
SG11202111877TA (en) 2021-11-29
BR112021021600A2 (pt) 2022-01-04
CA3138780A1 (en) 2020-11-05
US20220211703A1 (en) 2022-07-07
TWI736243B (zh) 2021-08-11
CN114007619B (zh) 2024-08-06
JP7665529B2 (ja) 2025-04-21
AU2020265327A1 (en) 2021-12-16
JP2022530890A (ja) 2022-07-04
EP3960179A4 (en) 2023-01-25
EP3960179A1 (en) 2022-03-02
KR102935436B1 (ko) 2026-03-05
MX2021013338A (es) 2022-01-24
KR20220007620A (ko) 2022-01-18
TW202106302A (zh) 2021-02-16

Similar Documents

Publication Publication Date Title
AU2020305979B2 (en) Method for treating idiopathic pulmonary fibrosis
AU2020230574B2 (en) Method for treating fatty liver disease and/or steatohepatitis
AU2020265327B2 (en) Method for treating cough by using diaminopyrimidine compound
AU2020266947B2 (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
JPH0269417A (ja) 精神分裂病治療用組成物
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
CA3138780C (en) Method for treating cough by using diaminopyrimidine compound
US20080312253A1 (en) Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
EP4591863A1 (en) Method for treating pneumoconiosis
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
MX2024009372A (es) Sales de adicion de acidos, composiciones y metodos de tratamiento de las mismas.
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
JPS61267520A (ja) 医薬組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)